RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...

The phase 3 VOLGA trial looks at perioperative durvalumab plus enfortumab vedotin, with and without tremelimumab, for muscle-invasive bladder cancer.

Key points of this article The turning point for mid-career interviews at Bristol Myers Squibb (hereinafter BMS) is whether ...

Key TakeawaysTempus AI shares rose 6% today after Bristol Myers Squibb agreed to license Tempus’s oncology data through 2031 and use its Lens AI platform. Bristol Myers Squibb is a returning customer ...

Pathos AI signed two collaborations with Bristol Myers Squibb (BMS) and Tempus AI to accelerate drug development for ...

A patient with highly active relapsing multiple sclerosis died of septic pneumonia after receiving Bristol Myers Squibb’s ...

The BMS has inaugurated its first formal divisional office in Kashmir's Awantipora. The permanent Sangh-linked presence has ...

In the Breakfree-2 study, the majority of adverse events were brief and reversible, generally consistent with previously reported zola-cel Phase 1 clinical trial data.

| Pathos AI has closed a $237 million series E round led by pharma giant Bristol Myers Squibb on the same day that the two companies signed a cutting-edge Alzheimer's disease-focused collaboration.

SRINAGAR: The Rashtriya Swayamsevak Sangh (RSS)-affiliated Bharatiya Mazdoor Sangh (BMS) has opened an office in Barsoo ...